CMP DEV LLC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CMP DEV LLC, and when can generic versions of CMP DEV LLC drugs launch?
CMP DEV LLC has six approved drugs.
There are twenty-three US patents protecting CMP DEV LLC drugs.
There are sixteen patent family members on CMP DEV LLC drugs in nine countries and fifty-two supplementary protection certificates in eleven countries.
Summary for CMP DEV LLC
| International Patents: | 16 |
| US Patents: | 23 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 6 |
Drugs and US Patents for CMP DEV LLC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | CAROSPIR | spironolactone | SUSPENSION;ORAL | 209478-001 | Aug 4, 2017 | AB | RX | Yes | Yes | 10,660,907 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Cmp Dev Llc | LIQREV | sildenafil citrate | SUSPENSION;ORAL | 214952-001 | Apr 28, 2023 | DISCN | Yes | No | 11,464,778 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Cmp Dev Llc | ATORVALIQ | atorvastatin calcium | SUSPENSION;ORAL | 213260-001 | Feb 1, 2023 | RX | Yes | Yes | 11,654,106 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Cmp Dev Llc | CAROSPIR | spironolactone | SUSPENSION;ORAL | 209478-001 | Aug 4, 2017 | AB | RX | Yes | Yes | 11,389,461 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Cmp Dev Llc | LIQREV | sildenafil citrate | SUSPENSION;ORAL | 214952-001 | Apr 28, 2023 | DISCN | Yes | No | 11,337,979 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | 11,253,474 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Cmp Dev Llc | CAROSPIR | spironolactone | SUSPENSION;ORAL | 209478-001 | Aug 4, 2017 | AB | RX | Yes | Yes | 10,888,570 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CMP DEV LLC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | 112020012986 | ⤷ Subscribe |
| Morocco | 50320 | ⤷ Subscribe |
| Australia | 2018397436 | ⤷ Subscribe |
| Japan | 2021509114 | ⤷ Subscribe |
| Morocco | 43132 | ⤷ Subscribe |
| Canada | 3086881 | ⤷ Subscribe |
| European Patent Office | 3731870 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for CMP DEV LLC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0443983 | C00443983/03 | Switzerland | ⤷ Subscribe | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
| 0720599 | 92545 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910 |
| 1499331 | 13C0055 | France | ⤷ Subscribe | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220 |
| 1915993 | 300625 | Netherlands | ⤷ Subscribe | PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414 |
| 0503785 | C300375 | Netherlands | ⤷ Subscribe | PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819 |
| 0463756 | 99C0007 | Belgium | ⤷ Subscribe | PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622 |
| 0740668 | PA2003001,C0740668 | Lithuania | ⤷ Subscribe | PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
